» Articles » PMID: 18727648

Medication Overuse Headache: Predictors and Rates of Relapse in Migraine Patients with Low Medical Needs. A 1-year Prospective Study

Overview
Journal Cephalalgia
Specialties Neurology
Psychiatry
Date 2008 Aug 30
PMID 18727648
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this study was to evaluate the rates and predictors of relapse, after successful drug withdrawal, in migraine patients with medication overuse headache (MOH) and low medical needs. The study population, study design, inclusion criteria and short-term effectiveness of the medication withdrawal strategies have been described elsewhere (Rossi et al., Cephalalgia 2006; 26:1097). Relapsers were defined as those patients fulfilling, at follow-up, the new International Classification of Headache Disorders, 2nd edn, appendix criteria for MOH. Complete datasets were available for 83 patients. At 1 year's follow up, the relapse rate was 20.5%. Univariate analysis showed that patients who relapsed had a longer duration of migraine with more than eight headache days/month, a longer duration of drug overuse, had tried a greater number of preventive treatments in the past, had a lower reduction of headache frequency after withdrawal, and had previously consulted a greater number of specialists. Binary logistic regression analysis was performed, and three variables emerged as significant predictors of relapse: duration of migraine with more than eight headache days/month [odds ratio (OR) 1.57, P = 0.01], a higher frequency of migraine after drug withdrawal (OR 1.48, P = 0.04) and a greater number of previous preventive treatments (OR 1.54, P = 0.01). In patients with migraine plus MOH and low medical needs, relapse seems to depend on a greater severity of baseline migraine.

Citing Articles

Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache - a retrospective real-world analysis.

Scheffler A, Basten J, Menzel L, Binz D, Becker W, Breunung V J Headache Pain. 2024; 25(1):109.

PMID: 38965463 PMC: 11225246. DOI: 10.1186/s10194-024-01813-3.


A Descriptive Review of Medication-Overuse Headache: From Pathophysiology to the Comorbidities.

Ljubisavljevic S, Ljubisavljevic M, Damjanovic R, Kalinic S Brain Sci. 2023; 13(10).

PMID: 37891777 PMC: 10605322. DOI: 10.3390/brainsci13101408.


Medication-overuse headache-a review of different treatment strategies.

Krymchantowski A, Jevoux C, Krymchantowski A, Ramos L, Barbosa J, Silva-Neto R Front Pain Res (Lausanne). 2023; 4:1103497.

PMID: 37881687 PMC: 10597723. DOI: 10.3389/fpain.2023.1103497.


Prevention of medication overuse and medication overuse headache in patients with migraine: a randomized, controlled, parallel, allocation-blinded, multicenter, prospective trial using a mobile software application.

Diener H, Donoghue S, Gaul C, Holle-Lee D, Jockel K, Mian A Trials. 2022; 23(1):382.

PMID: 35546412 PMC: 9092034. DOI: 10.1186/s13063-022-06329-2.


The burden of medication overuse headache and patterns of switching and discontinuation among triptan users: a systematic literature review.

Deighton A, Harris L, Johnston K, Hogan S, Quaranta L, LItalien G BMC Neurol. 2021; 21(1):425.

PMID: 34727873 PMC: 8561931. DOI: 10.1186/s12883-021-02451-x.